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Acylation-stimulating protein (ASP) acts as a para-
crine signal to increase triglyceride synthesis in adipo-
cytes. In mice, C3 (the precursor to ASP) knock-out (KO)
results in ASP deficiency and leads to reduced body fat
and leptin levels yet they are hyperphagic. In the pres-
ent study, we investigated the mechanism for this en-
ergy repartitioning. Compared with wild-type (WT)
mice, male and female C3(/) ASP-deficient mice had
elevated oxygen consumption (VO2) in both the active
(dark) and resting (light) phases of the diurnal cycle:
8.9% males (p < 0.05) 9.4% females (p < 0.05). In-
creased physical activity (movement) was observed dur-
ing the dark phase in female but not in male KO animals.
Female WT mice moved 16.9  2.4 m whereas KO mice
moved 30.1  5.4 m, over 12 h, 78.4%, p < 0.05). In
contrast, there was no difference in physical activity in
male mice, but a repartitioning of dietary fat following
intragastric fat administration was noted. This was re-
flected by increased fatty acid oxidation in liver and
muscle in KO mice, with increased UCP2 (inguinal fat)
and UCP3 (muscle) mRNA expression (p  0.005 and
0.036, respectively). Fatty acid uptake into brown adi-
pose tissue (BAT) and white adipose tissue (WAT) was
reduced as reflected by a decrease in the fatty acid in-
corporation into lipids (BAT 68%, WAT 29%. The de-
crease of FA incorporation was normalized by intraperi-
toneal administration of ASP at the time of oral fat
administration. These results suggest that ASP defi-
ciency results in energy repartitioning through differ-
ent mechanisms in male and female mice.
Acylation-stimulating protein (ASP)1 is an adipocyte-derived
protein that has potent anabolic effects on human adipose
tissue where it increases glucose uptake and non-esterified
fatty acid (NEFA) storage (1, 2) via translocation of glucose
transporters (GLUT1, GLUT3, and GLUT4) from intracellular
sites to the cell surface (3, 4) and activation of diacylglycerol
acyltransferase (DGAT) (2). These effects appear to be medi-
ated through specific cell surface binding (5, 6) resulting in
activation of a signal pathway that includes protein kinase C
(7). In addition, ASP has been shown to inhibit hormone-sen-
sitive lipase in adipocytes, independently and additively to
insulin (8). There is a differentiation-dependent increase in
ASP binding and ASP response in human adipocytes (1). The
major site of action of ASP is adipocytes, as determined by
competitive binding, stimulation of triglyceride synthesis, en-
hanced glucose transport, and transporter translocation (5).
ASP is identical to C3adesArg, a cleavage product of comple-
ment C3. Cleavage of complement C3 is mediated through the
alternate complement pathway via the interaction of C3, factor
B, and adipsin that generates C3a. Rapid cleavage of the C-
terminal arginine of C3a by carboxypeptidase N generates ASP
(9). Adipocytes are one of the few cells capable of producing all
three factors (factor B, adipsin, and C3) that are required for
the production of ASP (10). ASP production increases conse-
quent to adipocyte differentiation (11) and plasma ASP levels
are elevated in obesity (12, 13). In vitro chylomicrons stimulate
ASP production by adipocytes (14, 15). In vivo arterial-venous
gradients across a subcutaneous adipose tissue bed in humans
demonstrate direct postprandial production of ASP (16). The
postprandial increase in ASP is adipose tissue specific and is
not observed in the general circulation (17). Altogether, these
data suggest that ASP and lipid storage are metabolically
intertwined.
ASP acts as an adipocyte autocrine factor and we propose
that it plays a central role in the metabolism of adipose tissue
by increasing the efficiency of triglyceride synthesis in adipo-
cytes, an action that results in more rapid postprandial lipid
clearance (18). As ASP is derived through cleavage of comple-
ment C3, C3 knock-out mice (C3/) are necessarily deficient
in ASP. We have previously demonstrated that genetic defi-
ciency of ASP leads to reduced body fat and decreased leptin
levels (19, 20). In addition, male mice have delayed triglyceride
clearance (16, 20) although this has not been demonstrated in
all studies (21). Studies with double knock-out mice (C3/,
ob/ob) further demonstrated a resistance to development of
obesity, delayed triglyceride synthesis and demonstrated that
these effects of ASP were independent of leptin.
Strikingly, however, although ASP-deficient mice (C3/)
have decreased body weight and delayed TG and NEFA clear-
ance, they have a marked increased in food intake. This raised
the question: why are ASP-deficient mice leaner if they ingest
more caloric energy? We addressed that question by examining
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energy expenditure and postprandial fat partitioning during
resting and active phases of the diurnal (light:dark) cycle.
MATERIALS AND METHODS
Generation and Genotyping of Mice—The genetic background of the
mice used in this study was 129Sv. Complement C3 knock-out (C3/)
mice (129Sv  C57B6 genetic background), as well as wild-type mice,
were originally obtained from Dr. Harvey Coulton. Mice were back-
crossed 8–10 generations to obtain a homogenous 129Sv genetic back-
ground. (C3/) 129Sv back-crossed mice demonstrate a distinct delay
in triglyceride clearance, which the C57Bl/6 (C3/) mice do not,
although the reduced leptin and leanness were evident in both back-
crossed strains (18). Mice were housed in a pathogen-free barrier facil-
ity, 21 °C, 12 h dark/12 h light cycle, and fed regular rodent chow food.
All procedures on mice followed the guidelines established by the CACC
and were approved by the Royal Victoria Hospital Animal Care Com-
mittee. The mice were selected by genotyping with PCR as described
previously for C3 using tail tips collected when the mice were weaned at
3 weeks of age (19, 20).
Oxygen Consumption, Respiratory Quotient (RQ), Physical Activity,
Body Weight, Food Intake, and Body Composition—Mice were fed a low
fat diet (10% of daily caloric intake being provided by fat), which
represents a normal mouse chow diet. This diet contained 19.3% pro-
tein, 67.3% carbohydrate, and 4.3% fat w/w. The mice were weighed
weekly, and the food was weighed three times weekly to determine food
intake. Body composition analysis was measured with calculation of
percent water, fat, and protein.
Metabolic rate and activity was measured using the Integra ME
System from AccuScan Instruments, Inc. (Columbus, OH). The system
consists of an O2 analyzer, CO2 analyzer and a PhysioScan analyzer,
which monitors all vertical, horizontal, and ambulatory movement via
light beam interruptions. A flow controller/channelyzer allows for flow
rate adjustments and for sequential channeling of the airflow from the
air reference line and the four animals chambers through the CO2 and
O2 analyzer. The plexiglass animal chambers were 16  16  8 inches.
Animals were provided with their standard food and water while in the
chambers, and were acclimated to the chambers for 18 h immediately
prior to the 24 h data collection period. The Integra ME software
includes an O2 and CO2 analyzer calibration program and data collec-
tion and analysis programs. Reported values include O2 consumption,
CO2 production, RQ, heat production, total ambulatory movement and
total rest time.
Intragastric Fat Administration—After an overnight fast (16 h), 400
l of olive oil labeled with 50 Ci of [3H]oleate (followed by 100 l of air
above the oil) was administered by gastric gavage using a feeding tube
(12-cm curved ball tipped feeding needle, Ref. 22) according to standard
procedures as previously published (19, 20, 23–26). Where indicated,
ASP was injected intraperitoneally at the time of fat administration.
ASP was purified and injected as described previously (7, 27). Each
mouse received intraperitoneal injections of either sterile ASP (500 g)
dissolved in 300 l of phosphate-buffered saline, pH 7.4, containing 1
mg/ml fatty acid free bovine serum albumin (Sigma) or sterile vehicle
(same solution without ASP). Previous experiments have demonstrated
that injection of the vehicle solution (1 mg/ml bovine serum albumin in
phosphate-buffered saline, 300 l) had no effect of postprandial TG
clearance in the mice compared with the same mice without vehicle (19,
20). Blood was collected at the time points indicated for analysis. Total
muscle tissue weight was calculated as 25% of body weight based on
previous published data in 129Sv mice (28).
Plasma Assays—Blood was collected (at the indicated ages) for TG
and NEFA from overnight (16 h) fasted mice (with water ad libitum) or
after intragastric fat administration. Blood was separated by centrifu-
gation and stored at 80 °C until analysis. Plasma non-esterified fatty
acids (NEFA), triglyceride, and glucose were measured using colorimet-
ric enzymatic kits (Roche Applied Science). Insulin, adiponectin, and
leptin were measured by commercial immunoassay (Linco Research,
Inc).
Tissue Analysis—The mice were anesthetized with a mixture of 5 ml
of Ketamine (100 mg/ml), 2.5 ml of xylazine (20 mg/ml), 1 ml of
aceprozamine (10 mg/ml), and 1.5 ml of sterile saline amounting to 0.01
ml/10 g body weight. They were then sacrificed by cervical dislocation.
The following tissues were excised: spleen, kidney, heart, skeletal mus-
cle (quadriceps), liver, intrascapular brown adipose tissue (BAT), peri-
toneal adipose tissue, gonadal adipose tissue, pectoral adipose tissue,
inguinal adipose tissue, intestine, and stomach. The samples were
weighed and frozen in liquid nitrogen at 80 °C for later analysis.
Tissue fragments (10–50 mg) were extracted to measure total lipid and
separated from fatty acid oxidation products. Following extraction with
2 ml of chloroform/methanol (2:1), samples were mixed overnight. On
the following day, 1 ml of 50 mM CaCl2 was added, and the suspension
was centrifuged at 3000 rpm 4 °C for 20 min to achieve a phase sepa-
ration. The total lipids in the chloroform/methanol layer were sepa-
rated, evaporated and resuspended in chloroform/methanol (2:1) for
separation by thin layer chromotagraphy as previously published to
quantify triglyceride, diglyceride, fatty acid, and polar lipids by scintil-
lation counting (29). The aqueous phase containing oxidation products
was counted directly.
UCP mRNA Expression—Separate sets of wild-type and KO mice
were sacrificed for RNA analysis. Tissues were collected and immedi-
ately frozen in liquid nitrogen, then stored at80 °C until analysis. The
primers used for testing were: UCP-1: sense 5-AGCAA GAGGAAGG-
GACGCTC-3 (38–57 bp), antisense 5-TTCGGAAGTTGTCGGGTT
TC-3 (255–237 bp). UCP-2: sense 5-GTTTCGTCTCCCAGCCATTT-
T-3 (61– 80 bp), antisense 5-TGATTTCCTGCTACCTCCCA-3
(290–271 bp) and UCP-3: sense 5-ACTGTATGCTGAAGATGGTGGC-
T-3 (925–946 bp), antisense 5-AATGTTAGGCATCCAACCG-3
(1315–1287 bp). 18 S was used as housekeeping gene (Ambion).
Total RNA was isolated from the four tissue samples from each
mouse, using the TRIzol method (Invitrogen, Life Technologies, Inc.).
Reverse-transcription was performed using 3 g RNA and Moloney
murine leukemia virus reverse transcriptase in buffer containing
dNTPs, RNase inhibitor and oligo(dT) primer (Invitrogen, Life Technol-
ogies, Inc.). The resulting cDNA (RT mixture) was subjected to PCR.
Briefly, 2 l of cDNA and UCP-1, 2, or 3 primers (1 M final concen-
tration) were mixed with 0.5 units of TaqDNA polymerase/reaction tube
in standard buffer (0.2 mM dNTPs, 100 M TMAC, and MgCl2 diluted to
2 mM). The cDNA was amplified for 5 min at 95 °C followed by 30 cycles
of (1 min 95 °C, 1 min 60 °C and 1 min 72 °C), followed by 7 min 72 °C.
The PCR components (Taq polymerase, MgCl2, PCR buffer, primers,
104 M TMAC (tetramethylammonium chloride)) were all obtained from
Invitrogen, Life Technologies, Inc.
The amplified cDNA was separated by electrophoresis on 7.5% poly-
acrylamide gel in 1.5 mM Tris-HCl, pH 8.8 buffer at 200 V, with silver
staining (BioRAD) and dried. Quantification was done by gel scanning,
using the Molecular Analyst kit (BioRAD), referenced against DNA
concentration standards (BioRAD) that were electrophoresed with ev-
ery gel. Results were expressed as a ratio of specific UCP/18 S RNA.
Statistical Analysis—All results are presented as average  stand-
ard error (S.E.). Statistical comparisons were by Student’s t tests or
ANOVA, as indicated in the text and figure legends. Statistical signif-
icance was set at p  0.05, where NS indicates not significant.
RESULTS
We have previously reported that C3(/) ASP-deficient
mice (KO) have reduced body weight, adipose tissue mass, and
plasma leptin but consume 30% more energy compared with
WT mice (19, 20). This was also true of the present study where
KO mice had a reduced body weight and increased food intake.
Leptin levels were reduced: WT 6.23  1.45 versus KO 4.23 
0.70 ng/ml, p  0.05. Body composition analysis demonstrated
decreases in percent fat in KO as compared with WT: WT male
23.15%  1.64 versus KO male 16.02%  0.77 p  0.05 and WT
female 18.28%  1.16 versus KO female 14.74%  0.88 p 
0.05, g fat/g carcass weight, ANOVA  0.003.
In addition, we have previously demonstrated that ASP-
deficient C3(/) mice have increased insulin sensitivity as
reflected by decreased HOMA (homeostatic model assessment)
based on fasting insulin and glucose levels (19, 20), even when
the mice are backcrossed onto an obese (ob/ob) background (30).
ASP-deficient mice also demonstrate enhanced clearance of
glucose following an oral fat load and an oral glucose tolerance
test (19, 20). In the present study, the KO mice also demon-
strated decreases in insulin relative to glucose and lower
HOMA where the values were: WT 3.48  0.19 versus KO
3.64  0.14 mM of glucose, WT 9.46  1.22 versus KO 7.90 
0.56 u/ml insulin and WT 1.46  0.22 versus KO 1.21  0.11
mM u/ml for HOMA.
WT and KO mice were randomly selected except for the
experiments with intragastric fat administration on male mice.
In this case, we deliberately matched the body weights of the
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KO and WT mice to avoid a partitioning bias resulting from a
difference in adipose tissue mass and body weight (thus the KO
mice were, on average, 2 weeks older).
Oxygen Consumption and Physical Activity (Movement) Mon-
itoring—Mice were monitored for 42 h continuously, from 14:00
on day 1 to 8:00 on day 3. To allow for acclimation, only data
from the final 24 h are reported (8:00 day 2 to 8:00 day 3). The
mice were allowed to eat, drink, and move about freely. Move-
ment was recorded, and the ambient gas was sampled and
analyzed every 3 min. As shown in Fig. 1, in wild-type mice
(both male and female), oxygen consumption (VO2 measured as
ml/kg/min) was greater in the active phase (20:00–8:00) and
less in inactive phase (8:00–20:00) and the KO mice main-
tained this pattern. Interestingly, female mice had greater
oxygen consumption than the male mice (both WT and KO) and
this was confirmed in additional experiments where the mice
were tested in a pairwise fashion. Both male and female KO
mice had higher VO2 in the active phase compared with wild-
type mice (12 h active phase mean VO2, 2-way ANOVA, p 
0.0039 males, p  0.027 females). The differences were also
significant when calculated as area under the curve (measured
as ml O2/BWˆ.67/min; p 0.032 males, p 0.031 females). The
KO males had higher inactive phase VO2 than WT, calculated
as area under the curve (AUC) of VO2 (p  0.05, Table I). VO2
during the inactive phase was not different between the KO
and WT females.
KO female mice showed a substantial (78.4%, p  0.05)
increase in active phase movement (physical activity, Fig. 2)
compared with WT females, but there were no differences in
either active or inactive phase movement between KO and WT
male mice. The diurnal pattern of the RQ was similar in the
female KO and WT mice, while the KO males had a very slight
increase in AUC of RQ during the active phase compared with
WT males (Table I). On the other hand, measurement of rectal
body temperature did not detect any significant differences
between the groups when tested over a range of ages (5–30
weeks) and body weight (20–40 g): WT male 37.8  0.13, KO
male 37.7  0.12, WT female 37.7  0.10, and KO female
37.9  0.07 °C, n  20–30 mice per group).
Fat Administration in Male Mice—Three groups of body
weight matched male mice were tested: 6 wild-type mice, 6 KO
mice and 6 KO mice that received intraperitoneal (IP) injec-
tions of ASP at the same time as the intragastric fat bolus.
Body weight for the groups was chosen so as to not be different
(WT 25.9  0.7 versus KO 25.0  0.8 g), thus the KO mice were
slightly older. Following an overnight fast, a fat load of olive oil
containing [3H]oleate was given to the mice, and serial blood
samples was taken over 6 h (0, 1, 2, 3, 4, and 6 h). All the mice
were sacrificed at 6 h after the fat load to determine [3H]oleate
distribution in various tissues. Even though the KO mice were
matched for body weight to WT mice, KO mice had clearly
delayed TG clearance (incremental AUC: WT 1.7  0.4 mMh,
KO 6.1  1.2 mMh, p  0.01; KO with IP ASP 3.8  0.7 mMh,
p 0.05 versus KO and versus WT) and NEFA clearance (AUC:
WT 5.6  0.1 mMh, KO 7.0  0.5 mMh, p  0.05; KO with IP
ASP 6.0  0.5 mMh, p  0.05 versus KO) after the fat load.
Injecting ASP at the time of fat administration (time  0)
partially normalized both TG and NEFA clearance (Fig. 3).
There was no significant difference in the amount of [3H]oleate
remaining in intestine and stomach in the three groups of
animals (data not shown). We have previously reported that
ASP deficiency did not alter fat absorption (19, 20).
[3H]Oleate incorporation was measured in spleen, kidney,
heart, skeletal muscle, liver, BAT, peritoneal adipose tissue,
gonadal adipose tissue, pectoral adipose tissue, and inguinal
adipose tissue in all three groups of mice (WT, KO, KO IP
ASP). Data are reported as total [3H]oleate radiolabel incorpo-
rated per organ (Fig. 4). For muscle, total body muscle mass
was estimated as 25% of body weight according to previously
published data (28). For both WT and KO mice, most of the
absorbed radiolabel (average 92%) was present in the combined
tissues of liver, muscle, and BAT. For the male KO mice, there
was a 63% increase (p  0.05) in muscle radiolabel (WT
5.14  0.39, KO 8.37  0.79, KO with IP ASP 5.66  0.65
million dpm) and a 50% increase in liver radiolabel (WT
2.32  0.27, KO 3.50  0.26, KO with IP ASP 2.80  0.06
million dpm) compared with WT; but a 59% decrease (p 
0.05) in 3H radiolabel in BAT (WT 1.75  0.31, KO 0.71  0.25,
KO with IP ASP 2.20  0.61 million dpm, p  0.05) (Fig. 4).
Administration of ASP in KO mice normalized [3H]oleate tissue
uptake in these three tissues (Fig. 4). However, there was no
difference in total counts in white adipose tissue (Fig. 4) or in
spleen, kidney, or heart for all three groups (data not shown).
We then subfractionated the radiolabel into lipid and non-
lipid (oxidation products) components. As shown in Fig. 5, in
both BAT and WAT there were significant decreases in
[3H]oleate incorporation into the lipid component (p  0.05),
which were normalized to the WT level by ASP administration
(BAT: WT 1.67 0.20, KO 0.53 0.20, KO with IP ASP 1.33
0.15 million dpm; WAT: WT 0.65  0.05, KO 0.46  0.04, KO
with IP ASP: 0.68  0.04 million dpm). This decrease in
[3H]oleate incorporation was reflected primarily in a decrease
in the triglyceride/diglyceride ratio (BAT: WT 186.1 37.1, KO
84.8  25.0, p  0.05, KO with IP ASP 185.8  31.7 versus KO
p 0.05; WAT: WT 27.0 5.0, KO 9.8 0.8, p 0.05, KO with
IP ASP: 8.3  0.5), which indicated that there was relatively
less diglyceride converted into triglyceride in KO in these tis-
FIG. 1. KO mice have increased oxygen consumption: oxygen
consumption was tested over 36 h. Samples were recorded every 3
min. Both male and female KO mice had significantly increased oxygen
consumption compared with the wild-type group, where the number of
mice was: male n  5 (5 KO and 5 WT), female n  6 (6 KO and 6 WT).
The data were analyzed using 2-way ANOVA; active phase (20:00–
8:00) p  0.0039 males, p  0.027 females; no significant difference in
inactive phase (8:00–20:00).
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sues. On the other hand, in these tissues, there was no change
in the aqueous phase radiolabel, which represents fatty acid
oxidation products (data not shown).
Quite different results were obtained in muscle and liver. As
also shown in Fig. 5, in KO mice, compared with WT mice,
there was significant increase in [3H]oleate radiolabel in the
aqueous phase representing fatty acid oxidation products (mus-
cle: WT 5.07  0.33, KO 7.99  0.47, KO with IP ASP 5.48 
0.52 million dpm; liver: WT 0.65  0.04, KO 0.99  0.06, KO
with IP ASP 0.62  0.02 million dpm; p  0.05 both in muscle
and liver resulting in a 52% increase in the liver and a 60%
increase in muscle, both p 0.05. On the other hand, there was
no difference in the total lipid fraction, nor was there a differ-
ence in the proportion in TG in either liver or muscle: in
muscle, WT 63.1%  7.4, KO 73.3%  5.5, and KO  ASP
IP 64.9%  4.0, p  NS and in liver, WT 88.1%  1.5, KO
87.4%  1.9, and KO  ASP IP 87.6%  1.0, p  NS). ASP
injection at the same time as the intragastric fat administra-
tion in male KO mice resulted in a 37% decrease in liver (p 
0.05) and a 31% decrease in muscle (p  0.05) oxidation
products with no difference found in total lipid phase. These
data suggest that in male KO mice the absorbed fat was par-
titioned differently compared with WT mice, with greater up-
takes into muscle and liver. Specifically, oxidation in liver and
muscle appear to be increased significantly.
The changes in [3H]oleate radiolabel uptake, especially in
fatty oxidation products, point to changes in oxidation/thermo-
genesis, which may be associated with changes in plasma adi-
ponectin or UCPs. No difference in plasma adiponectin was
detected in male KO versus WT mice (WT: 46.6  5.8, KO:
48.1  4.3 ng/ml, p  NS). UCP mRNA expression normalized
to 18s was tested in muscle, BAT and WAT. As shown in Table
II and Fig. 6, UCP1 expression was decreased in BAT, muscle,
inguinal, and gonadal fat. These decreases may relate to the
lower serum leptin in KO mice (19, 20) also confirmed here,
since leptin stimulates UCP1 (31). On the other hand, there
were significant increases in inguinal fat UCP2 (p  0.02) and
muscle UCP3 (p  0.036, Table II).
DISCUSSION
The results presented here indicate that C3() ASP-deficient
KO mice, both male and female, have increased oxygen con-
sumption in the active phase and that male mice may also have
increased oxygen consumption in the inactive phase. Increased
activity, an important source of the energy expenditure change,
was observed in the female KO mice, but not in the male KO
mice. Both WT and KO male mice had decreased energy ex-
penditure compared with the female mice. Intragastric fat ad-
ministration resulted in increased fat oxidation in the liver and
muscle of male KO mice, consistent with the observed UCP3
overexpression in muscle.
Interestingly, the increased physical activity was only de-
tected in female KO mice, suggesting that the sex hormones (or
X-linked genes) may have a function in regulating energy ex-
penditure. Estradiol has been shown to enhance energy ex-
penditure by stimulating voluntary exercise as pointed out by
Wade (see review, Ref. 32). Similarly, ovariectomy caused a
sharp decrease in running wheel activity in rats and treatment
TABLE I
Oxygen Consumption (VO2) and Respiratory Quotient (RQ) in ASP-deficient C3 (/) and wild-type male and female mice
Male Female
Active phasea Inactive phaseb Active phase Inactive phase
VO2-AUC (L/Kg) WT 106.5  2.0 73.9  1.3 133.7  1.5 75.4  1.8
KO 116.0  2.9 81.7  2.9 144.0  2.6 78.3  1.1
Increase 8.9% 10.6% 9.4% 2.8%
p 0.05 0.05 0.05 NSc
RQ-AUC (min) WT 1180.0  6.4 645.7  13.0 1237.9  15.9 647.9  16.5
KO 1210.0  7.2 644.5  13.0 1247.9  15.7 655.8  8.3
Increase 2.5% 0.1% 0.8% 1.2%
p 0.05 NS NS NS
a The active phase was from 20:00-8:00.
b The inactive phase was from 8:00-20:00.
c NS, not significant.
FIG. 2. Female KO mice have increased movement compared
with WT mice during the active phase (20:00–8:00, 78.4%). There
are no differences between male KO and WT mice. All mice had in-
creased movement in active phase. * indicates KO versus WT, p  0.05,
where the number of mice was: male n 5 (5 KO and 5 WT), female n
6 (6 KO and 6 WT).
FIG. 3. Male KO mice have delayed postprandial TG and NEFA
clearance compared with WT mice. A fat load was administered to
KO and WT mice. Injection of ASP to one group of KO mice immediately
before the fat load partially restores the efficiency of TG and NEFA
clearance, where values are shown as for n  6 per group (6 WT, 6 KO,
6 KO with IP ASP). The data were analyzed using ANOVA where p 
0.05 for KO versus WT.
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with estradiol reinstated high levels of voluntary exercise (32,
33). Intracerebral implants of estradiol in or near these estro-
gen receptor-containing sites also increased activity in ovarec-
tomized rats (32, 34). Lesions that include the medial preoptic
area prevented the increases in activity induced by systemic
estradiol treatment, but not those induced by other treatments,
such as food deprivation or amphetamines (32, 35). Thus, the
estradiol stimulation of physical activity may be one way in
which the female KO mice compensate and dispose of the
excess energy ingested but not stored in adipose tissue.
Whether these effects of estradiol are in any way directly
related to the absence of ASP is unknown, but there is evidence
that estradiol enhances C3 expression (32, 36). As a hypothesis,
the effect of estrogen on energy expenditure may be counter-
balanced by stimulation of C3 and thus ASP, increasing storage
of fatty acid into adipose tissue. The absence of C3 in the KO
mice may unbalance the system leading to estrogen increases
in voluntary exercise in female KO mice.
With regard to the mechanism underlying the increased
energy expenditure in male KO animals, this could not be
explained on the basis of increased physical activity, as this
was not increased in males, but only in female mice. We ob-
served a clear increase in fatty acid oxidation products in both
muscle and liver and specific increases in UCP mRNA expres-
sion in certain tissues. It should be noted that there was an
increase in oxidation products, but no increase in lipid (espe-
cially triglyceride) products, therefore the increased uptake in
these tissues would not be expected to lead to lipotoxicity.
Absence of ASP results in reduced TG synthesis in adipocytes
and leads to delayed NEFA and TG postprandial clearance.
This delay in TG and NEFA clearance may be a function of
reduced uptake and esterification into TG (as reflected by the
decreased [3H]TG in adipose tissues) as well as reduced inhi-
bition of hormone sensitive lipase (both mediated by ASP) (8).
Both of these effects will contribute to the increased circulating
fatty acid flux, which in turn can lead to local inhibition of
lipoprotein lipase (product inhibition). These substrates may
then be redirected to muscle and liver for energy production.
The accumulation of radiolabeled lipid in ASP-deficient mice
into liver and muscle, caused by impaired lipid transportation
into adipocytes, appears to simulate what is observed in the
environment of high fat diet consumption. The increased en-
ergy expenditure would appear to be a systemic response to
this challenge. In mice, thermogenesis in brown adipose tissue
appears to be an important regulator of high fat diet induced
obesity, mediated by UCP1 and UCP2 (37). In the case of KO
FIG. 4. Radiolabeled [3H]oleate in-
corporation into individual tissues in
KO, WT, and ASP injected mice at 6
hours. For the male KO mice, 6 h after
fat load, 3H radiolabel was tested in dif-
ferent tissues. There were significant in-
creases in muscle and liver of KO mice
compared with WT mice but a significant
decrease in 3H radiolabel in BAT. Admin-
istration of ASP in KO mice restored the
changes. Values are shown as n  6 per
group (6 WT, 6 KO, 6 KO with IP ASP)
where *, KO versus WT, p  0.05; **, KO
with IP ASP versus KO, p  0.05).
FIG. 5. Radiolabeled [3H]oleate incorporation into total lipids
and oxidation products in specific tissues in KO, WT, and ASP-
injected mice at 6 hours. At 6 h after the fat load, different tissues
were extracted and the extractions were separated into total 3H-radio-
labeled lipid (top panel) and 3H-radiolabeled fatty acid oxidation prod-
ucts (bottom panel). Total radiolabeled lipids were significantly de-
creased in BAT and WAT, while oxidation products were significantly
increased in muscle and livers of KO mice. Administration of ASP in KO
mice could restore the changes. Values are shown as n  6 per group (6
WT, 6 KO, 6 KO with IP ASP) where *, KO versus WT, p  0.05; **, KO
with IP ASP versus KO, p  0.05).
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mice lacking ASP, brown adipose tissue does not appear to
function as efficiently as in WT mice since UCP1 is decreased.
Unlike UCP1, UCP2 is widely expressed (38), whereas UCP3 is
predominantly expressed in skeletal muscle (22, 23). In the
ASP-deficient mice, other tissues (muscle and fat) may par-
tially compensate for reduced BAT function through increases
in UCP2 and UCP3 expression. It has been clearly shown, both
in rodents and humans, that administration of fatty acids
increases muscle UCP3 expression (39, 40). However, UCP3 is
also regulated by several factors, including thyroid hormone,
3-adrenergic agonists and leptin as well as fat feeding in
rodents (24–26). One or more of these factors may be respon-
sible for the up-regulation of UCP3 in the ASP-deficient mice.
There is a striking difference in the metabolic adaptations in
mice with decreased adipose tissue triglyceride resulting from
partial reduction in stored energy (i.e. lean mice), as in the
present study, versus those mice that completely lack adipo-
cytes to store lipid (lipodystrophic mice). Mice that lack adipose
tissue completely are uniformly insulin resistant and hyperin-
sulinemic with markedly increased plasma triglycerides, de-
creased or absent leptin and accumulation of triglyceride in
non adipose tissue sites such as liver and muscle (41, 42). In
contrast, lean mice (as in the present study) are typically in-
sulin sensitive with normal or increased insulin sensitivity,
and normal plasma and liver triglycerides (see review, Ref. 43).
There is a multiplicity of mechanisms that can result in lean-
ness, but they all generally result in an imbalance in the energy
equation such that energy storage and energy expenditure
change (review in Refs. 43 and 44). Four mechanisms by which
this is achieved include: (i) reduced energy availability through
decreased intestinal absorption, (ii) increased peripheral en-
ergy metabolism in muscle, adipose tissue or elsewhere, (iii)
altered CNS regulation, or (iv) primary defect in peripheral
adipose tissue storage. In the first instance, energy input is
reduced, while in the remaining three the decreased energy
storage is a consequence of substrate re-partitioning and se-
questering in other tissues, oxidizing energy that would other-
wise be stored.
The intricate balance between energy intake, energy storage
and energy oxidation is intriguing. Various CNS-mediated
gene targets result in a lean phenotype, often with increased
metabolic rate but rarely a compensatory increase in food in-
take. Such examples are overexpression of leptin (45), melanin
concentrating hormone knock-out (46) and muscarinic M3 re-
ceptor knock-out (47, 48). Many transgenic or knock-outs, such
as UCP1 and UCP3 overexpression (49, 50), muscle LPL over-
expression (51, 52) and RII subunit of protein kinase A knock-
out (53, 54) that result in increased muscle or adipose tissue
oxidation and substrate repartitioning are partially compen-
sated by CNS-mediated increases in food intake, although ad-
ipose tissue mass still remains below normal.
In addition, disturbances directly in adipose tissue storage
capacity, induced by disruption of a number of genes, including
acetyl-CoA carboxylase 2 (55), acyl-CoA diacylglycerol acyl-
transferase (56) and complement C3(/) ASP deficiency as
reported here, all result in a reduced ability to store TG, or
enhanced lipolysis. What is particularly noteworthy, is that
this reduced energy storage consistently results in increased
energy expenditure due to repartitioning of energy substrates,
to the point where increased food intake cannot compensate.
The second striking point is that despite decreased substrate
storage in adipose tissue, the increased flux to other tissues
does not appear to result in deleterious consequences, such as
accumulation of muscle or liver TG or increased lipoprotein
production, but in fact the leanness appears to be associated, if
anything, with increased insulin sensitivity and improved lipid
profiles (43). In many of these lean models of primary adipose
tissue dysfunction, the site of increased energy expenditure
remains unknown but may be mediated through increased
uncoupling proteins or increased substrate cycling. Future
studies will need to focus on the mechanisms responsible for
the increased metabolism through in vitro experiments in tis-
sues such as muscle and liver.
In conclusion, ASP is an important factor in regulating met-
abolic balance. The absence of ASP production results in in-
creased energy expenditure in both male and female mice.
Male and female KO mice employ different mechanisms to deal
with the substrate not stored in adipose tissue resulting from
impaired TG synthesis. However, animals of both genders ex-
hibit a lean, insulin sensitive phenotype despite significant
hyperphagia.
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